CDC issues guidance on prioritizing new RSV treatment for infants
The Centers for Disease Control and Prevention Oct. 23 released interim for clinicians with limited access to the monoclonal antibody nirsevimab, recently approved to prevent respiratory syncytial virus in children aged 2 and under. The guidance calls for prioritizing 100 milligram doses of the treatment for infants under 6 months old and infants at high risk for severe disease due to underlying health conditions, among other recommendations.
Related News Articles
Headline
The American College of Obstetricians and Gynecologists April 17 released guidance recommending a new approach to prenatal care delivery. The guidance calls…
Headline
The National Institutes of Health April 7 released a study that found twins — smaller at birth on average than singletons — develop slower in early pregnancy…
Headline
A National Institutes of Health study published April 2 found that blood pressure patterns observed during the first half of pregnancy can determine a woman's…
Headline
The U.S. birth rate fell 2% in 2023 to about 3.6 million, according to final data released March 18 by the Centers for Disease Control and Prevention. The…
Headline
A study by the Penn State Department of Nutritional Sciences found that low vitamin D levels in the first trimester of pregnancy are associated with higher…
Headline
The U.S. maternal mortality rate decreased to 18.6 deaths per 100,000 live births in 2023, down from 22.3 in 2022, according to new data from the Centers for…